COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England

Freja C. M. Kirsebom, Nick Andrews, Julia Stowe, Samuel Toffa, Ruchira Sachdeva, Eileen Gallagher, Natalie Groves, Anne-Marie O’Connell, Meera Chand, Mary Ramsay, Jamie Lopez Bernal
doi: https://doi.org/10.1101/2022.03.22.22272691

Article usage

Article usage: March 2022 to January 2025

AbstractFullPdf
Mar 2022321938967
Apr 20223646941076
May 2022137643430
Jun 20226378268
Jul 202254024166
Aug 202239528106
Sep 202226510113
Oct 20222321232
Nov 2022194925
Dec 2022135835
Jan 2023119920
Feb 202398715
Mar 202397810
Apr 202370922
May 202366612
Jun 202342108
Jul 202361912
Aug 2023651711
Sep 20231191110
Oct 2023531413
Nov 202337113
Dec 202334126
Jan 202438107
Feb 202431128
Mar 20244182
Apr 202440915
May 202433128
Jun 202430611
Jul 2024211011
Aug 202440108
Sep 2024531016
Oct 202422105
Nov 2024301015
Dec 202422613
Jan 20252294
Back to top
Posted March 24, 2022.
Download PDF

Supplementary Material

Data/Code
Email
COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England
Freja C. M. Kirsebom, Nick Andrews, Julia Stowe, Samuel Toffa, Ruchira Sachdeva, Eileen Gallagher, Natalie Groves, Anne-Marie O’Connell, Meera Chand, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2022.03.22.22272691; doi: https://doi.org/10.1101/2022.03.22.22272691
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area